Tremfya competitors?

Tremfya (guselkumab) is a fully human monoclonal antibody that blocks IL‑23, used mainly for moderate‑to‑severe plaque psoriasis.
Below is a quick snapshot of the drugs that usually fill the same therapeutic niche – the “competitors” in the psoriasis market:

| Drug (brand) | Mechanism / Target | Typical Use | Key Differentiator |
|--------------|-------------------|-------------|--------------------|
| Stelara (ustekinumab) | IL‑12/23 p40 subunit | Plaque psoriasis, psoriatic arthritis, Crohn’s disease | First IL‑12/23 blocker; longer dosing interval (every 12 weeks after the first 6 months) |
| Cosentyx (secukinumab) | IL‑17A | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis | Rapid onset; every 4 weeks (maintenance 8 wks) |
| Taltz (ixekizumab) | IL‑17A | Plaque psoriasis, psoriatic arthritis | Very fast onset, 3‑month dosing interval in many patients |
| Risankizumab (Skyrizi/Rezurock) | IL‑23 p19 subunit | Plaque psoriasis, psoriatic arthritis | Similar target to Tremfya but slightly different epitope |
| Siliq (brodalumab) | IL‑17 receptor A | Plaque psoriasis | Unique IL‑17 receptor blockade |
| Humira (adalimumab) | TNF‑α | Plaque psoriasis, psoriatic arthritis, Crohn’s disease | TNF blocker; long track record |
| Enbrel (etanercept) | TNF‑α | Same as Humira | Soluble TNF receptor |
| Cimzia (certolizumab pegol) | TNF‑α | Psoriasis, Crohn’s disease | Pegylated Fab’ fragment; no Fc region |
| Remicade (infliximab) | TNF‑α | Plaque psoriasis, Crohn’s disease | IV infusion; strong anti‑TNF efficacy |
| Otezla (apremilast) | PDE‑4 inhibitor | Plaque psoriasis, psoriatic arthritis | Oral small‑molecule option |

How they stack up with Tremfya

• Efficacy: All these biologics are highly effective for moderate‑to‑severe plaque psoriasis. Head‑to‑head trials show slightly different PASI‑90/PASI‑75 rates; some clinicians prefer Tremfya for patients who haven’t responded to IL‑17 blockers.
  
• Safety: The IL‑23 pathway (Tremfya, Risankizumab) is associated with a lower risk of infection compared to TNF blockers, while IL‑17 blockers can increase the risk of candidiasis and neutropenia.
  
• Dosing: Tremfya is usually given at week 0, 4, then every 8 weeks, which is convenient. IL‑17 agents often require more frequent dosing initially.
  
• Cost & Insurance: All are high‑cost biologics; insurance formulary placement can differ, but many payers favor the newer IL‑23 agents (Tremfya, Risankizumab) for cost‑effectiveness.
  
  When picking a therapy, clinicians weigh a patient’s prior biologic exposure, comorbidities, infection history, and personal preference. If you’re a patient, discuss these options with your dermatologist to find the best fit for your specific situation.